# OnCo record compass-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/compass-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "compass-therapeutics" ;
  schema:name "Compass Therapeutics"@en ;
  schema:description "Compass makes antibodies that hit two targets at once to reshape the blood supply and immune environment of tumours. Its lead drug, tovecimig, blocks two blood-vessel growth signals and is heading for a possible US approval filing in bile duct cancer."@en ;
  schema:url <https://onco.cc/companies/compass-therapeutics/>, <https://www.compasstherapeutics.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.compasstherapeutics.com/>, <https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/tovecimig/> .